DRD1抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 30 μg, Lane: Hela cells, Primary antibody: P03864(DRD1 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P03864(DRD1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The dopamine receptor D1 (DRD1) is a G protein-coupled receptor that plays a central role in mediating dopamine signaling in the central nervous system. As a member of the D1-like receptor family (alongside DRD5), it primarily activates adenylyl cyclase via Gs proteins, increasing intracellular cAMP levels. DRD1 is highly expressed in brain regions critical for cognitive and motor functions, including the prefrontal cortex, striatum, and hippocampus. It is implicated in regulating reward mechanisms, locomotor activity, and executive functions. Dysregulation of DRD1 signaling has been associated with neurological and psychiatric disorders such as Parkinson's disease, schizophrenia, addiction, and attention deficit hyperactivity disorder (ADHD).

DRD1 antibodies are essential research tools for detecting and quantifying DRD1 expression in various experimental models. These antibodies enable the investigation of receptor localization, density, and trafficking through techniques like immunohistochemistry, Western blotting, and flow cytometry. Specificity validation (e.g., knockout controls) is crucial due to structural similarities among dopamine receptor subtypes. Both monoclonal and polyclonal DRD1 antibodies are available, typically generated against epitopes in extracellular or intracellular domains. Recent applications extend to studying receptor oligomerization, ligand interactions, and therapeutic target validation in neurodegenerative diseases. Challenges remain in developing antibodies that distinguish between post-translationally modified forms or species-specific variants of DRD1.